Improvement in MRI outcomes across subgroups with alemtuzumab versus interferon beta-1a in treatment-naive relapsing-remitting multiple sclerosis

被引：0
|
作者：
Montalban, X. [1 ]
Arnold, D. L. [2 ,3 ]
Fisher, E. [4 ]
Margolin, D. H. [5 ]
Palmer, J. [5 ]
机构：
[1] Vall dHebron Univ Hosp & Res Inst, Edifici Cemcat, Barcelona, Spain
[2] NeuroRx Res, Montreal, PQ, Canada
[3] McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada
[4] Cleveland Clin, Dept Biomed Engn, Cleveland, OH 44106 USA
[5] Genzyme, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P039
引用
收藏
页码：83 / 84
页数：2
相关论文
共 50 条
  • [21] Alemtuzumab improves MRI outcomes regardless of subgroup versus interferon beta-1a in relapsing-remitting MS patients who relapsed on prior therapy
    Barkhof, F.
    Fisher, E.
    Palmer, J.
    Margolin, D. H.
    Arnold, D. L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 100 - 101
  • [22] Consistent efficacy of alemtuzumab in relapsing-remitting multiple sclerosis across major demographic subgroups
    Bass, A. D. D.
    [J]. MULTIPLE SCLEROSIS, 2007, 13 (09): : 1219 - 1220
  • [23] Effect of Alemtuzumab vs. Interferon beta-1a on Brain Atrophy in Patients with Early, Active Relapsing-Remitting Multiple Sclerosis
    Zivadinov, Robert
    Dwyer, Michael
    Bergsland, Niels
    Hussein, Sara
    Durfee, Jackie
    Ramasamy, Deepa
    Cherneva, Mariya
    Willis, Laura
    Cox, Jennifer
    Kennedy, Cheryl
    Margolin, David
    Rizzo, Marco
    Palmer, Jeffrey
    [J]. NEUROLOGY, 2011, 76 (09) : A388 - A388
  • [24] COST-EFFECTIVENESS OF DACLIZUMAB VERSUS INTERFERON BETA-1A IN THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES
    Rao, D.
    Heidari, E.
    Kamal, K. M.
    Dashputre, A. A.
    [J]. VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [25] Effect of interferon beta-1a on grey matter atrophy progression in relapsing-remitting multiple sclerosis
    Zivadinov, R
    Locatelli, L
    Srinivasaraghavan, B
    Ukmar, M
    Bratina, A
    Maggiore, C
    Bosco, A
    Grop, A
    Pozzi-Mucelli, R
    Catalan, M
    Zorzon, M
    [J]. MULTIPLE SCLEROSIS, 2005, 11 (01): : 115 - 115
  • [26] Effect of Intramuscular Interferon beta-1a on Gray Matter Atrophy in Relapsing-Remitting Multiple Sclerosis
    Nakamura, Kunio
    Rudick, Richard
    Lee, Jar-Chi
    Foulds, Pamela
    Fisher, Elizabeth
    [J]. NEUROLOGY, 2010, 74 (09) : A407 - A407
  • [27] Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis
    De Stefano, Nicola
    Curtin, Francois
    Stubinski, Bettina
    Blevins, Gregg
    Drulovic, Jelena
    Issard, Delphine
    Shotekov, Penko
    Gasperini, Claudio
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (07) : 888 - 892
  • [28] The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
    Dupuy, Sheena L.
    Khalid, Fariha
    Healy, Brian C.
    Bakshi, Sonya
    Neema, Mohit
    Tauhid, Shahamat
    Bakshi, Rohit
    [J]. BMC MEDICAL IMAGING, 2016, 16
  • [29] Health economic evaluation of interferon beta-1a versus interferon beta-1b for patients with relapsing-remitting multiple sclerosis in Switzerland
    Nuijten, M. J. C.
    Chofflon, M.
    [J]. MULTIPLE SCLEROSIS, 2007, 13 : S262 - S262
  • [30] Emerging Methods for Evaluating the Effectiveness of Intramuscular Interferon Beta-1a for Relapsing-Remitting Multiple Sclerosis
    Foley, John F.
    Barnes, Christopher J.
    Nair, Kavita V.
    [J]. JOURNAL OF MANAGED CARE PHARMACY, 2013, 19 (01): : S16 - S23
12345